Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10061543 | 0.98 | TDP1 (0.58) | TDP1L3MBTL1MAPTALDH1A1MAOB | |
| SCHEMBL8688325 | 0.98 | TDP1 (0.58) | TDP1L3MBTL1MAPTALDH1A1MAOB | |
| SCHEMBL29459491 | 0.95 | MAPT (0.60) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL5889451 | 0.95 | MAPT (0.60) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL25030174 | 0.89 | MAPT (0.50) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL30233911 | 0.89 | MAPT (0.50) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL6993290 | 0.87 | DRD3 (0.55) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL29459546 | 0.87 | DRD3 (0.55) | TDP1L3MBTL1MAPTALDH1A1RAB9A | |
| SCHEMBL6790333 | 0.84 | TDP1 (0.71) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7352103 | 0.84 | TDP1 (0.57) | TDP1L3MBTL1MAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100412073-C | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2008-08-20 | — | — | CN | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| CN-1665800-A | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0709386-B1 | FUSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMA CO LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-0060696-B1 | NITROGEN HETEROCYCLES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-01-15 | — | — | EP | disclosed |
| EP-0030092-B1 | GUANIDINE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-02-06 | — | — | EP | disclosed |
| EP-0045155-B1 | GUANIDINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-01-02 | — | — | EP | disclosed |
| US-4464374-A | Substituted guanidine derivatives, processes, pharmaceutical compositions and methods and intermediates | ICI AMERICAS INC. (US) | 1984-08-07 | — | — | US | disclosed |
| US-4460584-A | GUANIDINE DERIVATIVES, ANTISECRETORY AGENT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-07-17 | — | — | US | disclosed |
| US-4362728-A | Haloguanidine compounds, pharmaceutical compositions and methods of use | ICI AMERICAS INC. (US) | 1982-12-07 | — | — | US | disclosed |
| EP-0060696-A1 | Nitrogen heterocycles | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-09-22 | — | — | EP | disclosed |
| EP-0059597-A2 | Guanidino-substituted heterocyclic derivatives having histamine H-2 antagonist activity | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-09-08 | — | — | EP | disclosed |
| EP-0045155-A1 | Guanidine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-02-03 | — | — | EP | disclosed |
| EP-0030092-A1 | Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | TDP1 4176/4885L3MBTL1 1285/4885MAPT 3296/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | TDP1 3250/4885L3MBTL1 1375/4885MAPT 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.